DcR3 Antibody (G-4): sc-166176
- DcR3 Antibody (G-4) is a mouse monoclonal IgG2b κ provided at 200 µg/ml
- raised against amino acids 171-300 of DcR3 of human origin
- recommended for detection of DcR3 of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG2b BP-HRP are the preferred secondary detection reagents for DcR3 Antibody (G-4) for WB applications. These reagents are now offered in bundles with DcR3 Antibody (G-4) (see ordering information below).
QUICK LINKS
DcR3 Antibody (G-4) is a mouse monoclonal IgG2b light chain antibody that detects DcR3 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DcR3, or Decoy Receptor 3, plays a crucial role in modulating the immune response by acting as a decoy for pro-apoptotic ligands, particularly those from the tumor necrosis factor (TNF) superfamily. By binding to these ligands, DcR3 prevents them from interacting with death domain-containing receptors, thereby inhibiting apoptosis in cells that might otherwise undergo programmed cell death. This function is particularly important in the context of cancer, as tumor cells can exploit DcR3 to evade immune surveillance and resist apoptosis, contributing to tumor progression and metastasis. The ability of DcR3 to interfere with apoptotic signaling pathways highlights DcR3′s potential as a therapeutic target in cancer treatment, making anti-DcR3 antibody (G-4) an invaluable tool for researchers studying mechanisms of immune evasion and apoptosis in human cancers.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
DcR3 Antibody (G-4) References:
- Quantification and detection of DcR3, a decoy receptor in TNFR family. | Chen, J., et al. 2004. J Immunol Methods. 285: 63-70. PMID: 14871535
- Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. | Huang, S., et al. 2014. ScientificWorldJournal. 2014: 605236. PMID: 24741354
- Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases. | Zhang, Y., et al. 2016. Onco Targets Ther. 9: 4959-68. PMID: 27570459
- Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model. | Liu, YL., et al. 2017. Mol Neurodegener. 12: 30. PMID: 28438208
- DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis. | Li, J., et al. 2017. Oncotarget. 8: 107612-107620. PMID: 29296192
- Up-regulation of DcR3 in microbial toxins-stimulated HUVECs involves NF-κB signalling. | Hou, Y., et al. 2018. BMC Biochem. 19: 13. PMID: 30587127
- Role of TGFβ3-Smads-Sp1 axis in DcR3-mediated immune escape of hepatocellular carcinoma. | Zhu, HF., et al. 2019. Oncogenesis. 8: 43. PMID: 31409774
- DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop. | Wei, Y., et al. 2019. Am J Cancer Res. 9: 2618-2633. PMID: 31911850
- HIF-1α regulates DcR3 to promote the development of endometriosis. | Guan, J., et al. 2024. Eur J Obstet Gynecol Reprod Biol. 296: 185-193. PMID: 38458034
- DcR3 suppresses the NF-κB pathway and the NLRP3 inflammasome activation in gouty inflammation. | Jiang, Y., et al. 2024. Chin Med J (Engl). 137: 2644-2646. PMID: 39294866
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DcR3 Antibody (G-4) | sc-166176 | 200 µg/ml | $322.00 | |||
DcR3 Antibody (G-4): m-IgG Fc BP-HRP Bundle | sc-540036 | 200 µg Ab; 10 µg BP | $361.00 | |||
DcR3 Antibody (G-4): m-IgG2b BP-HRP Bundle | sc-549767 | 200 µg Ab; 10 µg BP | $361.00 |